Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. operates as a biopharmaceutical firm, concentrating its efforts on discovering and clinically developing novel therapeutic solutions. These treatments primarily leverage cannabinoids and are designed to enhance patients' quality of life. Currently, the company's leading investigational drug candidate is being advanced for the management of rheumatoid arthritis. Furthermore, Raphael Pharma plans to broaden its pipeline to include more cannabinoid-based medicines aimed at various cancer types and other autoimmune conditions. The company's corporate headquarters are situated in Tel Aviv-Jaffa, Israel.
Sector: Medicinal Chemicals & Botanical Products
Industry: Drug Manufacturers - Specialty & Generic
Raphael Pharmaceutical Inc.
OTC:RAPHHealthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap-
Float11.52M
O/S-
Inst Own-
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$1.28M
Total Assets$53K
Free Cash Flow-$210K
Debt & Equity
Total Debt$34K
Total Equity-$1.43M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in RAPH's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$53K
Liabilities$1.49M
Accounts Receivable$0
Accounts Payable$163K
Inventory$0
PP&E (Net)$2K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $631K | $776K | $569K | $1.18M | $776K |
| Selling, General, and Administrative | $614K | $733K | $763K | $2.14M | $853K |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $1.25M | $1.51M | $1.33M | $3.32M | $1.63M |
| Operating Income (EBIT) | -$1.25M | -$1.51M | -$1.33M | -$3.32M | -$1.63M |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $18K | $2K | $3K | $3K | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $5K |
| Other Income (Expense) | -$34K | -$10K | -$12K | -$41K | $5K |
| Income Before Tax (EBT) | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.62M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.62M |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -0.07 | -0.08 | -0.08 | -0.23 | -0.10 |
| Diluted EPS | -0.07 | -0.08 | -0.08 | -0.23 | -0.10 |
| Weighted Average OS | 19.55M | 18.67M | 16.72M | 14.34M | 15.48M |
| EBITDA | -$1.25M | -$1.51M | -$1.33M | -$3.32M | -$1.63M |
| EBITDA Margin | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $45K | $19K | $230K | $288K | $153K |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $45K | $19K | $230K | $288K | $153K |
| Accounts Receivable | $0 | $2K | $7K | $38K | $92K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $6K | $0 | $0 | $0 | $0 |
| Total Current Assets | $51K | $25K | $237K | $331K | $422K |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $2K | $2K | $2K | $2K | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $2K | $2K | $2K | $2K | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $53K | $27K | $239K | $333K | $422K |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $163K | $125K | $69K | $72K | $107K |
| Short-Term Debt | $34K | $41K | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Current Liabilities | $1.49M | $769K | $132K | $227K | $294K |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.49M | $769K | $132K | $227K | $294K |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $202K | $187K | $185K | $157K | $130K |
| Retained Earnings | -$10.17M | -$8.89M | -$7.37M | -$6.03M | -$2.67M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $8.53M | $7.96M | $7.29M | $5.97M | $2.67M |
| Total Equity | -$1.43M | -$742K | $107K | $106K | $128K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $53K | $27K | $239K | $333K | $422K |
| Supplementary Data | |||||
| Total Debt | $34K | $41K | $0 | $0 | $0 |
| Net Debt | -$11K | $22K | -$230K | -$288K | -$153K |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$1.28M | -$1.52M | -$1.34M | -$3.36M | -$1.62M |
| Depreciation & Amortization | $0 | $0 | $0 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $245K | $390K | $200K | $2.29M | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $6K | $406K | -$130K | $102K | $234K |
| Other Working Capital | $818K | $191K | $71K | $207K | -$28K |
| Total Working Capital Change | $824K | $597K | -$59K | $309K | $206K |
| Other Non-Cash Items | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Operating | -$210K | -$532K | -$1.2M | -$759K | -$1.42M |
| Investing Activities | |||||
| Capital Expenditures | $0 | $0 | $0 | -$2K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $0 | -$2K | $0 |
| Financing Activities | |||||
| Debt Repaid | - | - | - | - | - |
| Common Stock Issuance | $243K | $280K | $1.15M | $896K | $1.29M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $0 | $0 | $13K |
| Net Cash from Financing | $236K | $321K | $1.15M | $896K | $1.48M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $26K | -$211K | -$58K | $135K | $58K |
| Supplementary Data | |||||
| Operating Cash Flow | -$210K | -$532K | -$1.2M | -$759K | -$1.42M |
| Capital Expenditure | $0 | $0 | $0 | -$2K | $0 |
| Free Cash Flow | -$210K | -$532K | -$1.2M | -$761K | -$1.42M |
| Cash at Beginning | $19K | $230K | $288K | $153K | $95K |
| Cash at End | $45K | $19K | $230K | $288K | $153K |